Ionis Pharmaceuticals (IONS) Posted Two Positive Phase 3 Trial Readouts

• Ionis Pharmaceuticals (NasdaqGS:IONS) reported two positive Phase 3 trial readouts on 24 September 2026 for late stage RNA-targeted drugs.
• Sefaxersen, partnered with Roche, met its primary endpoint in a Phase 3 study in IgA nephropathy, a chronic kidney disease.
• Ulefnersen, developed with Otsuka, achieved its main Phase 3 goal in patients with FUS-ALS, a rare and severe ALS subtype.
• The twin Phase 3 wins for sefaxersen and ulefnersen only capture part of what these data could mean for Ionis. Our analysis turns up 2 other big wins for Ionis Pharmaceuticals as well.

These RNA trial results at Ionis Pharmaceuticals sit inside a wider push to apply data driven drug discovery in healthcare, which connects directly to 38 healthcare AI stocks.

Ionis Pharmaceuticals is a US based biotech group focused on RNA targeted medicines, working with larger drug companies to bring its research through late stage trials and into the market. For investors, the partnerships with Roche and Otsuka highlight a model that relies on big pharma to help carry programs toward potential regulatory decisions.

Does the team leading Ionis Pharmaceuticals have what it takes? See our full breakdown of the management team's track record and compensation.

Positive Phase 3 data shifts Ionis Pharmaceuticals back toward a platform-driven story

The investment story for Ionis Pharmaceuticals has been about whether a focused RNA medicines platform can turn a handful of high-stakes programs into a broader revenue engine, especially after pelacarsen reset expectations. These Phase 3 readouts test that Narrative directly by adding new potential franchises in kidney disease and genetic ALS.

"Expanding into larger patient populations and strong physician acceptance position Ionis for substantial market share gains and sustained top-line growth...

See how the full story points towards a $88.00 fair value for Ionis Pharmaceuticals.

The sefaxersen IgA nephropathy and ulefnersen FUS-ALS results go straight to that idea of a platform that can reach beyond severe hypertriglyceridemia. They support the view that Ionis can keep adding clinically meaningful RNA drugs where big pharma partners like Roche and Otsuka handle heavy lifting on late-stage trials and potential commercialization.

The unresolved issue is whether these wins translate into the kind of pricing, access and patient volumes the Narrative assumes as Ionis moves into larger or more complex indications. Analysts have already flagged pricing pressure and execution around late-stage launches as key risks, and this news does not answer how payers or regulators will treat these specific assets.

For investors, the real signal here is not the trial headlines themselves but how they line up with whichever version of the Ionis Pharmaceuticals Narrative you choose to believe.

One piece of the Ionis Pharmaceuticals puzzle this article has not touched

Ionis Pharmaceuticals today is one story. The projections a few years out sketch something quite different, and the gap between those two views is where your real work starts. See where analysts expect Ionis Pharmaceuticals to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com